Bedrijfsvoering Amgen Inc.

AMGN

US0311621009

Farmaceutische producten

Geschatte realtime Cboe BZX Andere beurzen 21:18:16 15-01-2025			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
269,80 ^USD	+1,01%		+2,16%	+3,56%

14/01	Amgen Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 03:00 PM
10/01	AMGEN INC. : Wells Fargo Securities vindt het aandeel niet inspirerend	ZM

Uitvoerend comité: Amgen Inc.

Bedrijfsleider

Beklede functiesVan

Robert Bradway

62 jaar

Chief Executive Officer	01-05-2012
President	-

Victoria H. Blatter

General Counsel

Peter Griffith

66 jaar

Director of Finance/CFO

01-01-2020

Mike Zahigian

Chief Tech/Sci/R&D Officer

01-06-2017

Darryl Sleep

Chief Tech/Sci/R&D Officer

01-08-2018

Esteban Santos

57 jaar

Chief Operating Officer

25-07-2016

Jonathan Graham

64 jaar

General Counsel	13-07-2015
Corporate Secretary	13-07-2015

David Reese

62 jaar

Chief Tech/Sci/R&D Officer

26-07-2018

Nancy Grygiel

57 jaar

Compliance Officer

01-01-2016

Derek Miller

Human Resources Officer

Li Yang

56 jaar

Chief Tech/Sci/R&D Officer

Jean-Charles Soria

54 jaar

Chief Tech/Sci/R&D Officer

Paul Burton

56 jaar

Chief Tech/Sci/R&D Officer

01-06-2023

James Bradner

53 jaar

Chief Tech/Sci/R&D Officer

18-12-2023

Matthew Busch

51 jaar

Comptroller/Controller/Auditor

14-08-2023

Mark J. Taisey

General Counsel

01-01-2014

Susan Sweeney

Sales & Marketing

01-09-2019

Howard Y. Chang

Chief Tech/Sci/R&D Officer

16-12-2024

Samenstelling van de raad van bestuur: Amgen Inc.

Directeur

RadenVan

Robert Bradway

62 jaar

Executive Committee Chair	01-01-2013
Governance Committee	14-10-2016
Finance Committee Chair

Robert Eckert

70 jaar

Compensation Committee	26-03-2021
HR Committee	26-03-2021
Governance Committee Chair	26-03-2021
Nominating Committee Chair	26-03-2021
Executive Committee	01-01-2003
Governance Committee	20-03-2020
Nominating Committee	20-03-2020
Compensation Committee Chair

Charles Holley

68 jaar

Executive Committee	03-02-2017
Governance Committee
Nominating Committee	03-02-2017
Audit Committee Chair	01-04-2020
Audit Committee	04-10-2019
Finance Committee	04-10-2019

Ellen Kullman

69 jaar

Governance Committee Chair	08-05-2023
Nominating Committee Chair	08-05-2023
Audit Committee	14-10-2016
Governance Committee	21-12-2016
Nominating Committee	21-12-2016
Compensation Committee	21-12-2016

Wanda Austin

70 jaar

Compensation Committee	24-10-2017
Governance Committee Chair	01-12-2016
Nominating Committee Chair	01-12-2016
Audit Committee
Finance Committee

Amy Miles

58 jaar

Governance Committee	23-07-2020
Audit Committee Chair
Finance Committee Chair	01-04-2020
Audit Committee	23-07-2020
Nominating Committee	23-07-2020

Omar Ishrak

69 jaar

Audit Committee	01-08-2023
Finance Committee	23-01-2023
Governance Committee	01-08-2023
Nominating Committee	01-08-2023
Compensation Committee	30-07-2021

Greg Garland

67 jaar

Executive Committee
Compensation Committee	16-10-2013
Governance Committee Chair
Nominating Committee Chair

Brian Druker

69 jaar

Compensation Committee	23-05-2018
Governance Committee	23-12-2020
Nominating Committee	23-12-2020

Mary Klotman

70 jaar

Governance Committee	31-05-2024
Nominating Committee	11-11-2022
Compensation Committee	11-11-2022

Tyler Jacks

64 jaar

Finance Committee	24-02-2015
Compensation Committee

Michael Drake

74 jaar

Governance Committee	03-08-2022
Nominating Committee	03-08-2022

Recente benoemingen: Amgen Inc.

Akari Therapeutics, Plc kondigt bestuurswijzigingen aan	18/12	CI
Howard Chang treedt in dienst bij Amgen als Senior Vice President Research en Chief Scientific Officer, met ingang van 16 december 2024	20/11	CI
Collegium Pharmaceutical, Inc. kondigt wijzigingen aan in de functie van Chief Executive Officer, met ingang van 12 november 2024	07/11	CI
Carisma Therapeutics kondigt wijzigingen aan in de Raad van Bestuur	30-10-24	CI
Disc Medicine, Inc. Benoemt Rahul Kaushik tot Chief Technical Officer	23-10-24	CI
Mural Oncology plc benoemt Sachiyo Minegishi tot lid van de Raad van Bestuur	23-09-24	CI
Tyra Biosciences benoemt Doug Warner tot Chief Medical Officer	10-09-24	MT

Meer nieuws

Voormalige zaakvoerders en bestuurders: Amgen Inc.

Insider

Beklede functies

VanTot

Frank Herringer

Director/Board Member	01-05-2004	22-05-2019
Independent Dir/Board Member	22-04-2011	22-05-2019

David Baltimore

Director/Board Member	01-01-1997	22-05-2018
Independent Dir/Board Member	22-04-2011	22-05-2018

Frank J. Biondi

Director/Board Member	01-01-2002	19-05-2017
Independent Dir/Board Member	22-04-2011	19-05-2017

Judith C. Pelham

Director/Board Member	01-05-1995	19-05-2017
Independent Dir/Board Member	22-04-2011	19-05-2017

Rolf K. Hoffmann

Corporate Officer/Principal

01-11-2004

01-07-2016

Vance D. Coffman

Director/Board Member	02-10-2007	01-01-2016
Independent Dir/Board Member	22-04-2011	01-01-2016

Willard Dere

Chief Tech/Sci/R&D Officer	01-01-2007	01-04-2014
Corporate Officer/Principal	01-04-2014	01-10-2014

Joseph P. Miletich

Chief Tech/Sci/R&D Officer

01-04-2002

01-07-2014

Gilbert Omenn

Director/Board Member	01-01-1987	15-05-2014
Independent Dir/Board Member	22-04-2011	15-05-2014

Leonard Schaeffer

Director/Board Member	01-03-2004	08-07-2013
Independent Dir/Board Member	22-04-2011	08-07-2013

J. Reason

Director/Board Member	01-01-2001	22-05-2013
Independent Dir/Board Member	22-04-2011	22-05-2013

David Beier

Public Communications Contact	19-04-2011	08-10-2012
General Counsel	01-12-2003	08-10-2012
Corporate Officer/Principal	08-10-2012	01-01-2013

Fabrizio Bonanni

Chief Operating Officer

01-04-1999

01-01-2013

Kevin Sharer

Chief Executive Officer	01-01-2000	01-05-2012
Chairman	01-10-1992	31-12-2012
President	01-10-1992	01-01-2000

Roger Perlmutter

Chief Tech/Sci/R&D Officer

01-01-2001

12-02-2012

Roy Baynes

Corporate Officer/Principal

01-08-2002

01-01-2012

Frederick Gluck

Director/Board Member	01-02-1998	01-10-2011
Independent Dir/Board Member	22-04-2011	01-10-2011

Lisa Guttman

Corporate Officer/Principal

01-01-2000

01-10-2007

Richard Nanula

Director of Finance/CFO

01-08-2001

10-04-2007

Donald B. Rice

Director/Board Member

01-10-2000

17-01-2007

Lisa A. Evrén

Treasurer

01-01-2002

01-01-2007

Hassan A. Dayem

Chief Tech/Sci/R&D Officer

01-05-2002

20-09-2006

Timothy Martin

Comptroller/Controller/Auditor	01-08-2003	01-05-2006
Director of Finance/CFO	01-08-2003	01-05-2006

David Parkinson

Corporate Officer/Principal

01-05-2003

01-03-2006

Keith L. Klein

General Counsel

01-01-1991

01-01-2006

Edward V. Fritzky

Director/Board Member

01-07-2002

01-05-2005

Charles R. Bradley

Corporate Officer/Principal

01-01-2000

01-01-2005

Michael Narachi

Corporate Officer/Principal

01-07-1984

01-01-2003

Thomas James Flanagan

Chief Tech/Sci/R&D Officer

01-06-2004

Steve Lazarus

Director/Board Member

01-05-1987

13-05-2004

Patricia Cary Sueltz

Director/Board Member	08-01-2002	01-05-2004
Independent Dir/Board Member	08-01-2002	01-05-2004

David J. Scott

General Counsel	01-03-2004	-
Corporate Secretary	01-03-2004	-

Joseph J. Tsiakals

Corporate Officer/Principal

01-01-2000

01-01-2004

Bradley J. Maroni

Corporate Officer/Principal

01-01-1998

01-01-2004

Martha E. Vincent

Chief Tech/Sci/R&D Officer

01-01-1995

01-01-2004

Kevin B. Young

Corporate Officer/Principal

01-01-2001

01-01-2004

Wen-Tse Tseng

Corporate Officer/Principal

10-09-1998

10-09-2003

Diane M. Palumbo

Human Resources Officer

01-06-1991

01-07-2003

Carl LeBel

Corporate Officer/Principal

01-01-1993

David Hallal

Sales & Marketing

01-01-1992

01-08-2002

Nicholas Lydon

Corporate Officer/Principal

01-12-2000

02-01-2002

Robin D. Campbell

Corporate Officer/Principal

01-01-1989

01-01-2002

Brian M. McNamee

Human Resources Officer	01-06-2001	07-11-2013
Corporate Officer/Principal	07-11-2013	-

Matthew Moyle

Corporate Officer/Principal

01-01-1995

01-01-2001

Gordon Binder

Chief Executive Officer

01-01-1982

01-01-2000

Henry Wu

Corporate Officer/Principal

01-01-1999

Gisela Schwab

Chief Tech/Sci/R&D Officer

01-01-1992

Denny Lanfear

Corporate Officer/Principal

01-01-1986

01-01-1999

Jerry D. Choate

Director/Board Member	01-08-1998	-
Independent Dir/Board Member	22-04-2011	-

Danute M. Bankaitis-Davis

Chief Tech/Sci/R&D Officer

01-01-1992

01-01-1998

Rosemary Mazanet

Chief Tech/Sci/R&D Officer

01-01-1993

01-01-1998

Kathleen M. Wiltsey

Sales & Marketing

01-01-1984

01-01-1998

Julia Eastland

Director of Finance/CFO

01-01-1996

01-01-1998

Margaret E. Valeur-Jensen

Corporate Officer/Principal

01-01-1991

01-01-1998

Gregory Stea

Sales & Marketing

01-05-1988

01-01-1997

Peter García

Corporate Officer/Principal

01-01-1990

Richard Yeh

Corporate Officer/Principal

01-10-1995

Mark Moon

Corporate Officer/Principal

01-01-1989

02-01-1995

Lowell Sears

Director of Finance/CFO

01-01-1986

01-01-1994

Alan B. Forsythe

Corporate Officer/Principal

01-01-1991

G. Kirk Raab

Director/Board Member

01-01-1981

01-01-1985

Bertrand C. Liang

Corporate Officer/Principal

Joshua Disbrow

Corporate Officer/Principal

Alexander Lopez

Corporate Officer/Principal

Elaine Richardson

Corporate Officer/Principal

Howard J. Lewin

Corporate Officer/Principal

Edward H. Shin

Corporate Officer/Principal

David Polk

Public Communications Contact

Alec Green

Corporate Officer/Principal

Jeffrey D. Webster

Corporate Officer/Principal

M. Patricia Beckmann

Corporate Officer/Principal

Nancy Stuart

Corporate Officer/Principal

Ralph Niven

Corporate Officer/Principal

Kathleen Stafford

Treasurer

Steve Bandler

Corporate Officer/Principal

Sanjay Kanungo

Corporate Officer/Principal

Steven R. Wiley

Corporate Officer/Principal

James H. Chamberlain

Corporate Officer/Principal

John Shutter

Public Communications Contact

Luc Marengère

Corporate Officer/Principal

Ernest Allen

Corporate Officer/Principal

Leeftijdsdistributie van bedrijfsleiders

Ratio vrouwen/mannen

Man	27
Vrouw	9

Waarvan leden van het uitvoerend comité

Man	15
Vrouw	3

Waarvan bestuurders

Man	10
Vrouw	2

ESG MSCI

ESG

Milieu

Sociaal

Bedrijfsvoering

Controverse

Amgen Inc. is wereldwijd een van de grootste concerns voor biotechnologie. De omzet per inkomstenbron wordt als volgt onderverdeeld: - verkoop van medicijnen (95,5%): medicijnen bestemd voor de behandeling van kanker, problemen met de stofwisseling, botziektes, nierfalen, hemofilie, enz.; - overige (4,5%): met name royalty's. 70,3% van de omzet wordt gemaakt in de Verenigde Staten.

Werknemers

26.700

Sector

Farmaceutische producten

Agenda

04-02-2025 - Q4 2024 Cijferpublicaties

Meer informatie over het bedrijf